Premature Ventricular Contractions

Premature ventricular contractions (PVCs), also known as ventricular premature complexes (VPCs) or ventricular extrasystoles, are ectopic beats originating from the ventricular myocardium or the specialized conduction system distal to the bundle of His. They occur when an abnormal focus in the ventricles depolarizes earlier than the next expected sinus beat, leading to a premature, wide, and bizarre QRS complex on the electrocardiogram (ECG). PVCs can be isolated, uniform (monomorphic), multiform (polymorphic), or occur in patterns such as bigeminy, trigeminy, or couplets. They are a common arrhythmia in both dogs and cats and can be benign or indicative of significant underlying cardiac or systemic disease. The clinical significance of PVCs depends on their frequency, complexity, underlying heart disease, and hemodynamic impact.

PVCs can arise from a wide range of cardiac and non-cardiac causes. Primary cardiac etiologies include degenerative valvular disease (e.g., myxomatous mitral valve disease), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), myocarditis (infectious, immune-mediated, or toxic), myocardial infarction (rare in veterinary patients), cardiac neoplasia (e.g., hemangiosarcoma, chemodectoma), and congenital heart defects. Non-cardiac causes include electrolyte imbalances (hypokalemia, hypomagnesemia, hypercalcemia), acid-base disturbances, hypoxia, anemia, sepsis, systemic inflammatory response syndrome (SIRS), trauma, gastric dilatation-volvulus (GDV), splenic disease (e.g., hemangiosarcoma, torsion), pancreatitis, and endocrine disorders such as hyperthyroidism and pheochromocytoma. Drug-induced PVCs can result from digoxin toxicity, sympathomimetics (e.g., dobutamine, dopamine), anesthetics (e.g., halothane, thiopental), and certain antiarrhythmic drugs (e.g., sotalol, procainamide). Idiopathic PVCs, particularly in certain breeds like Boxers, are well-recognized.

PVCs are common in both dogs and cats. In dogs, they are frequently associated with underlying cardiac disease, with a higher prevalence in breeds predisposed to DCM (e.g., Doberman Pinschers, Great Danes, Boxers) and ARVC (Boxers). Myxomatous mitral valve disease, common in small breed dogs (e.g., Cavalier King Charles Spaniels, Dachshunds), can also lead to PVCs, especially in advanced stages. In cats, PVCs are often seen with hypertrophic cardiomyopathy, hyperthyroidism, and systemic hypertension. Age distribution varies: older animals are more likely to have degenerative or neoplastic causes, while younger animals may have congenital or inflammatory conditions. There is no strong sex predilection, though some studies suggest a slight male predominance in certain breeds. Geographic variation is minimal, but infectious causes (e.g., Chagas disease in endemic areas) can influence regional prevalence.

The pathophysiological mechanisms underlying PVCs include enhanced automaticity, triggered activity (early or delayed afterdepolarizations), and reentry. Enhanced automaticity occurs when ventricular myocytes or Purkinje fibers depolarize spontaneously at an accelerated rate, often due to increased sympathetic tone, hypokalemia, or ischemia. Triggered activity results from afterdepolarizations that reach threshold potential; early afterdepolarizations (EADs) occur during phase 2 or 3 of the action potential (often due to prolonged repolarization, e.g., from bradycardia or certain drugs), while delayed afterdepolarizations (DADs) occur after repolarization (often due to calcium overload, e.g., from digoxin toxicity or catecholamines). Reentry requires a unidirectional block and slow conduction, creating a circuit that generates repetitive ectopic beats. In diseased myocardium, fibrosis, inflammation, or infiltration disrupts normal conduction, facilitating reentry. PVCs can reduce cardiac output by interrupting effective ventricular filling and contraction, especially if frequent or occurring during the vulnerable period (R-on-T phenomenon), potentially precipitating ventricular tachycardia or fibrillation.

Predisposing factors for PVCs include underlying structural heart disease (e.g., DCM, HCM, valvular disease), myocardial ischemia or infarction, myocarditis, cardiac tumors, and congenital anomalies. Electrolyte disturbances, particularly hypokalemia and hypomagnesemia, increase myocardial excitability. Acid-base imbalances, hypoxia, and anemia can predispose to arrhythmias. Systemic diseases such as sepsis, pancreatitis, GDV, and splenic disease are associated with PVCs. Endocrine disorders like hyperthyroidism and pheochromocytoma increase catecholamine levels, promoting ectopy. Certain drugs (digoxin, anesthetics, sympathomimetics) and toxins (e.g., chocolate, oleander) are known triggers. Stress, pain, and intense exercise can also precipitate PVCs in susceptible animals. Breed-specific genetic predispositions are significant, especially in Boxers (ARVC) and Doberman Pinschers (DCM).

Clinical signs of PVCs vary from asymptomatic to severe. Many animals with occasional PVCs show no clinical signs. When PVCs are frequent or associated with underlying heart disease, signs may include weakness, lethargy, exercise intolerance, syncope, or collapse. In severe cases, especially with ventricular tachycardia or R-on-T phenomenon, sudden cardiac death can occur. Physical examination may reveal an irregular heart rhythm, pulse deficits, and possibly signs of congestive heart failure (e.g., dyspnea, crackles, jugular distension) if underlying cardiac disease is present. In cats, PVCs may be detected incidentally during examination for other conditions, but can also cause syncope or congestive heart failure. The clinical stage (peracute, acute, chronic) influences presentation: peracute onset may present with collapse, acute with weakness, and chronic with intermittent exercise intolerance.

Differential diagnoses for PVCs include other arrhythmias that cause an irregular rhythm or wide QRS complexes: (1) Supraventricular premature complexes (SVPCs) with aberrant conduction – these have a narrow QRS unless aberrancy occurs; differentiation relies on the presence of a preceding P wave and QRS morphology. (2) Atrial fibrillation – characterized by an irregularly irregular rhythm with no discernible P waves and a narrow QRS (unless concurrent bundle branch block). (3) Ventricular tachycardia – sustained runs of PVCs; may be monomorphic or polymorphic. (4) Accelerated idioventricular rhythm – a ventricular rhythm with a rate close to the sinus rate (often 60-100 bpm in dogs). (5) Sinus arrhythmia with wandering pacemaker – a normal variant with gradual changes in P wave morphology and rate. (6) Atrioventricular block (second-degree or third-degree) – may cause pauses and escape beats that can be mistaken for PVCs. (7) Electrode artifact or movement artifact – can mimic PVCs on ECG. (8) Hyperkalemia – can cause wide QRS complexes and bradycardia, but not typically premature. (9) Myocardial infarction – rare but can cause PVCs; diagnosis via troponin and ECG changes. (10) Cardiac neoplasia – may cause PVCs via myocardial infiltration; imaging and biomarkers help.

The diagnostic approach to PVCs begins with a thorough history and physical examination, including cardiac auscultation and palpation of femoral pulses. If an arrhythmia is suspected, a baseline ECG is obtained. If PVCs are intermittent, a 24-hour Holter monitor is recommended to quantify frequency and complexity. Echocardiography is essential to evaluate for structural heart disease. Blood work, including a complete blood count, serum biochemistry panel, and electrolytes (especially potassium, magnesium, calcium), is performed to identify metabolic abnormalities. Cardiac biomarkers such as cardiac troponin I (cTnI) and NT-proBNP may be measured to assess myocardial injury or stress. If myocarditis or systemic disease is suspected, additional tests such as infectious disease titers (e.g., for Borrelia, Ehrlichia, Anaplasma, Trypanosoma cruzi) or PCR may be indicated. In cases of suspected pheochromocytoma, abdominal ultrasound and plasma/urine metanephrines are considered. If a drug-induced cause is suspected, drug levels (e.g., digoxin) may be measured. Advanced imaging (e.g., cardiac MRI) is rarely needed but can be used to detect myocardial fibrosis or inflammation.

Laboratory findings in PVCs are often non-specific but can reveal underlying causes. Hematology may show anemia (which can cause hypoxia-induced ectopy), leukocytosis (suggesting infection or inflammation), or thrombocytopenia (e.g., with immune-mediated disease). Serum biochemistry may reveal electrolyte abnormalities: hypokalemia (K+ < 3.5 mEq/L), hypomagnesemia (Mg2+ < 1.5 mg/dL), hypercalcemia (Ca2+ > 12 mg/dL), or acid-base disturbances. Elevated cardiac troponin I (cTnI > 0.1 ng/mL) indicates myocardial injury. NT-proBNP may be elevated in heart disease. In cases of renal failure, BUN and creatinine are elevated. Hyperthyroidism in cats is diagnosed with elevated total T4. Pheochromocytoma may show elevated glucose and possibly hypertension. Urinalysis may reveal proteinuria or casts if systemic disease is present. Blood gas analysis can identify hypoxia or acidosis. Specific biomarkers like C-reactive protein (CRP) may be elevated in inflammatory conditions.

Imaging plays a crucial role in evaluating PVCs. Thoracic radiographs are useful to assess heart size, pulmonary vasculature, and signs of congestive heart failure (e.g., pulmonary edema, pleural effusion). Echocardiography is the gold standard for structural heart disease: it can identify chamber enlargement, wall thickness, valvular lesions, myocardial dysfunction (e.g., reduced ejection fraction), and pericardial effusion. Doppler echocardiography can assess diastolic function and estimate pressures. In cases of suspected cardiac neoplasia, echocardiography may reveal masses. Abdominal ultrasound is indicated if pheochromocytoma or splenic disease is suspected. Advanced imaging like cardiac MRI can detect myocardial fibrosis or inflammation, but is rarely used in veterinary practice. Holter monitoring is a form of ambulatory ECG that provides continuous recording over 24 hours, allowing quantification of PVC frequency and complexity.

Cytology and histopathology are not routinely performed for PVCs unless there is a suspicion of myocarditis, neoplasia, or infiltrative disease. Fine needle aspiration (FNA) of a cardiac mass (e.g., hemangiosarcoma) may be attempted under ultrasound guidance, but is risky due to bleeding. Histopathology of myocardial biopsies (obtained via thoracoscopy or at necropsy) can reveal inflammatory infiltrates (lymphocytic, neutrophilic), myocardial necrosis, fibrosis, or neoplastic infiltration. Special stains (e.g., Masson's trichrome for fibrosis, immunohistochemistry for tumor markers) may aid diagnosis. In cases of ARVC, histopathology shows fibrofatty replacement of the myocardium, particularly in the right ventricle.

Treatment of PVCs depends on the underlying cause and clinical significance. If PVCs are infrequent and no structural heart disease is present, no antiarrhythmic therapy may be needed; instead, treat any underlying metabolic or systemic condition. If PVCs are frequent, complex, or associated with clinical signs (syncope, weakness) or underlying heart disease, antiarrhythmic therapy is indicated. Emergency treatment for malignant ventricular arrhythmias (e.g., sustained ventricular tachycardia) includes intravenous lidocaine (dogs: 2-4 mg/kg IV bolus, then 25-80 µg/kg/min CRI; cats: 0.25-0.5 mg/kg IV slow bolus, then 10-20 µg/kg/min CRI) or procainamide (dogs: 6-8 mg/kg IV slow bolus, then 25-50 µg/kg/min CRI). For long-term management, oral antiarrhythmics include sotalol (dogs: 1-2 mg/kg PO q12h; cats: 1-2 mg/kg PO q12h), mexiletine (dogs: 4-8 mg/kg PO q8h), amiodarone (dogs: loading 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h), and beta-blockers (e.g., atenolol: dogs 0.25-1 mg/kg PO q12h; cats 6.25-12.5 mg/cat PO q12h). In cases of digoxin toxicity, digoxin immune Fab is indicated. Electrolyte imbalances should be corrected (e.g., potassium supplementation for hypokalemia, magnesium sulfate for hypomagnesemia). Underlying heart disease (e.g., DCM, HCM) should be treated appropriately (e.g., pimobendan, ACE inhibitors, diuretics). In cases of GDV or splenic torsion, surgical intervention is necessary. For refractory or life-threatening arrhythmias, radiofrequency catheter ablation may be considered in specialized centers.

The prognosis for PVCs is highly variable and depends on the underlying cause. Idiopathic PVCs in otherwise healthy animals generally have a good prognosis. However, PVCs associated with structural heart disease, such as DCM or ARVC, carry a guarded to poor prognosis, especially if frequent or complex. In Boxers with ARVC, the risk of sudden cardiac death is significant. PVCs secondary to transient metabolic disturbances or drug toxicity often resolve with correction of the underlying issue, leading to a good prognosis. The presence of syncope, ventricular tachycardia, or R-on-T phenomenon worsens the prognosis. Negative prognostic indicators include high PVC frequency (>10,000 PVCs/24h), multiform PVCs, couplets, and runs of non-sustained ventricular tachycardia. In cats with HCM and PVCs, the prognosis is guarded due to the risk of congestive heart failure and thromboembolism.

Follow-up for PVCs depends on the severity and underlying cause. For animals on antiarrhythmic therapy, re-evaluation with ECG and Holter monitoring is recommended within 1-2 weeks after initiating or changing therapy to assess efficacy and adverse effects. Serial Holter monitoring every 3-6 months is advised for chronic management. Serum drug levels (e.g., digoxin, amiodarone) should be monitored periodically. Electrolytes and renal function should be checked regularly, especially if diuretics or ACE inhibitors are used. Echocardiography should be repeated every 6-12 months to monitor progression of underlying heart disease. Owners should be educated to monitor for signs of weakness, syncope, or collapse. In cases of reversible causes, follow-up may be shorter. For animals with implantable cardioverter-defibrillators (rare in veterinary medicine), regular device checks are necessary.

Pearls: (1) Always evaluate PVCs in the context of the whole patient; not all PVCs require treatment. (2) A Holter monitor is essential for quantifying PVC burden and detecting complex forms. (3) Correct electrolyte imbalances before starting antiarrhythmic drugs, as hypokalemia can reduce efficacy. (4) In Boxers, PVCs may be the first sign of ARVC; consider Holter and echocardiography even in asymptomatic dogs. (5) In cats, hyperthyroidism is a common cause of PVCs; treat the thyroid disease first. Pitfalls: (1) Mistaking PVCs for supraventricular arrhythmias with aberrancy; careful ECG analysis is needed. (2) Over-treating benign PVCs with antiarrhythmics, which can have proarrhythmic effects. (3) Failing to identify underlying structural heart disease, leading to inappropriate therapy. (4) Using lidocaine in cats without caution, as it can cause CNS toxicity. (5) Ignoring the possibility of drug-induced arrhythmias, especially with digoxin or anesthetics.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: For emergency ventricular tachycardia: Lidocaine (dogs: 2-4 mg/kg IV bolus over 1-2 minutes, may repeat once after 5-10 minutes, then CRI 25-80 µg/kg/min; cats: 0.25-0.5 mg/kg IV slow bolus, then CRI 10-20 µg/kg/min). Procainamide (dogs: 6-8 mg/kg IV slow bolus over 5 minutes, then CRI 25-50 µg/kg/min; cats: 2-4 mg/kg IV slow bolus, then CRI 10-20 µg/kg/min). For long-term oral therapy: Sotalol (dogs: 1-2 mg/kg PO q12h; cats: 1-2 mg/kg PO q12h). Mexiletine (dogs: 4-8 mg/kg PO q8h; cats: not recommended). Amiodarone (dogs: loading 10-15 mg/kg PO q12h for 7 days, then 5-10 mg/kg PO q24h; cats: 10-15 mg/kg PO q24h, but use with caution). Atenolol (dogs: 0.25-1 mg/kg PO q12h; cats: 6.25-12.5 mg/cat PO q12h). For digoxin toxicity: Digoxin immune Fab (dose based on serum digoxin level). For electrolyte correction: Potassium chloride (IV or PO, dose based on deficit), Magnesium sulfate (0.5-1 mEq/kg IV over 4-6 hours). Always adjust doses for renal or hepatic impairment and monitor for adverse effects.

Key studies and consensus guidelines: The ACVIM consensus statement on the diagnosis and treatment of canine arrhythmias (2018) provides evidence-based recommendations for managing ventricular arrhythmias. Studies in Doberman Pinschers have shown that Holter monitoring is superior to ECG for detecting PVCs and predicting sudden death. The use of sotalol and mexiletine has been evaluated in dogs with DCM and ARVC, showing reduced PVC frequency. In Boxers with ARVC, sotalol has been shown to be effective in reducing ventricular arrhythmias. Amiodarone is reserved for refractory cases due to its side effects. In cats, beta-blockers are commonly used for PVCs associated with HCM, though evidence is limited. The use of cardiac troponin I as a biomarker for myocardial injury has been validated in several studies. Overall, management should be individualized based on underlying cause and clinical signs.